Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to treat cancer such as T cell receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines in fields of high medical need. The first product candidates are in clinical development and the Company has diverse preclinical programs.
Company Strategy
Medigene’s strategy is to develop its own therapies towards clinical proof-of-concept, starting with hematological malignancies, and advancing its technologies towards solid tumor indications. In addition, the Company offers selected partners the opportunity to discover and develop additional treatments on the basis of its technological platforms.
Short Profile
- Focus on T-cell-directed immunotherapies
- T cell receptor-modified T cell (TCR-T)-therapy MDG1011 in patients with indications with acute myeloid leukemia (AML) or myelodisplastic syndrome (MDS) in clinical Phase I/II trial and clinical Phase I trial with TCR-therapy MDG1021 in cancer patients suffering from relapse/persistence after allogeneic hematopoietic stem cell transplantation
- Terminated clincial Dendritic cell vaccines (DCs) phase I/II trial
- Over 100 employees with expertise in immunotherapy and pharmaceutical development
- Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
- Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00
Company History
| Year | Milestone |
|---|---|
| 1994 | Medigene founded as Munich Gene Center spin-off |
| 2000 | Medigene IPO listed on the Frankfurt Stock Exchange |
| 2001 | Medigene acquired US biotechnology company NeuroVir, Inc. |
| 2004 | Medigene acquired products and technology of Munich Biotech AG |
| 2004 | Medigene received first regulatory approval for cancer drug Eligard® in Germany |
| 2006 | Medigene acquired British biotechnology company Avidex Limited |
| 2006 | Medigene’s product Veregen® became the first FDA approved biopharmaceutical of a German biotech company in the USA |
| 2012-14 | Strategic repositioning through sale of Eligard®, EndoTAG® and RhuDex® |
| 2014 | Focus on immuno-oncology by strategic acquisition of Trianta Immunotherapies GmbH (renamed Medigene Immunotherapies GmbH) |
| 2015 | Start of Phase I/II study with DC vaccine clinical trial(FDC101) to treat AML |
| 2015 | Amgen acquires Medigene spin-off Catherex |
| 2016 | Start of Phase II part of the clinical trial with DC vaccine (FDC101) |
| 2016 | Medigene sells partial stake in Immunocore Ltd. |
| 2016 | bluebird bio and Medigene establish strategic T cell receptor alliance in cancer immunotherapy |
| 2017 | U.S.-rights for Veregen® are disposed |
| 2018 | Expansion of the bluebird bio partnership |
| 2018 | Start of Phase I/II study of MDG1011 in AML, MDS and MM |
| 2019 | Roivant and development Sinovant launch Cytovant Sciences in partnership with Medigene to develop cellular therapies in Asia with Cytovant/RoivantGreater China, South Korea and Japan |
| 2019 | Sale of remaining rights and inventories of Veregen® |
| 2020 | Publication of topline data from the DC vaccine trial (FDC101) |